OncoMatch/Clinical Trials/NCT05941741
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Is NCT05941741 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Immune checkpoint inhibitor and Chemotherapy for nasopharyngeal carcinoma.
Treatment: Chemotherapy · Immune checkpoint inhibitor — This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy (CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life in two groups.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T4N1M0, T1-4N2-3M0
Excluded: Stage DISTANT METASTASES
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiotherapy
Not received radiotherapy
Cannot have received: chemotherapy
Not received...chemotherapy
Cannot have received: immunotherapy
Not received...immunotherapy
Cannot have received: other anti-tumor treatment
Not received...other anti-tumor treatment
Lab requirements
Blood counts
white blood cell count ≥ 4×109/l, neutrophile granulocyte count ≥ 1.5×109/l, hemoglobin ≥ 9g/l, platelet count ≥ 100×109/l
Kidney function
blood urea nitrogen or creatinine ≤ 1.5×upper limit of normal or endogenous creatinine clearance ≥ 60ml/min (cockcroft-gault formula)
Liver function
alanine aminotransferase or aspartate aminotransferase < 2.5×upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05941741 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T4N1M0 or T1-4N2-3M0 is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages